Home page International biotech events Biosimilars and Biobetters

Biosimilars and Biobetters

Holiday Inn Kensington Forum, London UK (September, 30 - October, 1, 2015)

With Europe leading the way in the field of Biosimilar development, it is important to get to grips with all areas in the product lifecycle from early stage developments, protein characterisation and analytical comparability to patent litigation, market access, pricing and reimbursement through to emerging markets and global developments. Every angle should be considered and taken account for through the development process and with the EU the most advanced market for biosimilars, accounting for 80% of global spending on these molecules, the learning curve for biosimilars is essentially still building and there are hurdles to overcome. Against this backdrop, SMi’s 6th annual Biosimilars and Biobetters conference features a distinguished line-up of speakers who are pioneering the way in biosimilars and biobetters, including MHRA, GfK, Teva, Harvest Moon Pharmaceuticals USA Inc and more, as they present on the latest development on key topics including regulatory landscape, pharmacovigilance of biosimilars, patent litigation, market access and EU & global market developments.

Business Benefits of attending SMi’s 6th annual Biosimilars and Biobetters conference:

Hear the latest on the evolving regulatory biosimilar landscape and review the guidelines
Gain understanding on the barriers being faced for market access and commercialisation of products through case-study led presentations
Focus on the global market developments with case studies on the emerging markets of biosimilars and assessing the trends we are currently seeing
Assess and review in-depth protein characterisation and analytical comparability to efficiently and effectively collect data

Key Speakers include:

Chairperson: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
Shahin Kauser, Senior Scientific Assessor, MHRA
Chris Teale, Vice President Europe, GfK NOP Ltd
Bracha Timan, Director, Israel Site Head, Global Bioassays & Technology, Global R&D, Teva
Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
Karsten Roth, Director Clinical Operations, Cinfa Biotech GmbH
Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Health
Steinar Madsen, Medical Director, Norwegian Medicines Agency